Email Us
Call Us
GEMM-derived allograft models are established by transplanting tumor tissue from a genetically engineered mouse model into immunocompetent hosts of the same background. The result combines the genetic fidelity of an engineered model with the operational characteristics of an implanted one, which resolves the principal practical objection to GEMMs without abandoning what makes them useful.
Altogen Labs provides GDA model development for programs requiring an intact murine immune system, defined tumor genetics, and study timelines compatible with conventional efficacy work. To discuss model development for a specific genotype, request a quote.
What transplantation changes
A genetically engineered model requires breeding, genotyping, and a variable latency period before each animal develops a tumor, so cohorts assemble slowly and study start is staggered. Transplanting established tumor tissue into recipient animals removes all three constraints. Tumors initiate on a defined day, grow with predictable kinetics, and can be measured from a common baseline, so a study is powered and randomized in the same way as a conventional efficacy study.
Because recipients share the genetic background of the donor model, the graft is not rejected and the host immune system remains fully intact. This distinguishes the platform from human tumor xenografts, which require an immunodeficient host and therefore cannot support immune-dependent mechanisms at all.
What is lost is autochthonous initiation. The tumor is implanted rather than arising in native tissue, so the earliest stages of transformation and the tissue response to them are not represented. Where those stages are the object of study, the parent engineered model remains the appropriate platform.
Where GDA fits relative to other immunocompetent options
Syngeneic models use established murine tumor cell lines in matched immunocompetent hosts. They are fast, well characterized, and widely used for checkpoint inhibitor benchmarking, but the lines have been maintained in culture for decades and carry the mutational burden and phenotype that selection in vitro produced.
GDA models are derived from tumors that arose in vivo from defined genetic alterations, so the genetics are known by construction rather than inherited from a line’s history, and the tumor has not passed through extended culture. Where a program needs an immunocompetent model carrying specific driver alterations, and no syngeneic line carries them, a GDA model is frequently the only route.
Applications
Typical applications include immuno-oncology evaluation in an intact immune system with defined tumor genetics, comparative studies against a matched syngeneic line, combination work pairing an immunotherapy with a targeted agent directed at the engineered driver, and efficacy studies in indications where suitable syngeneic lines do not exist.
Applied examples
Genotype-matched immunotherapy. A checkpoint inhibitor is evaluated in allografts carrying a defined driver alteration, establishing whether response depends on that genotype in an immunocompetent setting.
Targeted and immune combination. An inhibitor of the engineered driver is combined with an immune agonist, with tumor response and intratumoral immune populations assessed by flow cytometry to establish whether the targeted agent alters the immune context.
Bridging from an engineered model. A finding first observed in a slow autochthonous model is confirmed in allografts derived from it, allowing a properly powered efficacy study on a conventional timeline.
Model characterization and scope
Growth kinetics, implantation parameters, and immune infiltration characteristics are established for each model before pharmacology studies are designed against it, since these determine cohort sizing, randomization volume, and study duration. Passage history is recorded, because serial transplantation can alter growth rate and immune phenotype and a model characterized at early passage may not behave identically later.
Model development methodology is not published, and establishment details are discussed under confidentiality. All procedures are conducted under active IACUC protocols, with humane endpoints and monitoring defined per model. GLP standards are applied where a study is formally designated as GLP.
Send genotype, indication, and study objective, or request a quote.